|
US2631173A
(en)
|
1949-01-04 |
1953-03-10 |
Phillips Petroleum Co |
Production of cyclooctadiene
|
|
IL54795A
(en)
|
1978-05-26 |
1980-10-26 |
Yeda Res & Dev |
Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
|
|
WO1989007970A1
(en)
|
1988-03-02 |
1989-09-08 |
Uab Research Foundation |
Reversible mechanochemical engines comprised of bioelastomers capable of modulable inverse temperature transitions for the interconversion of chemical and mechanical work
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
ES2234563T5
(es)
|
1999-02-12 |
2018-01-17 |
Daiichi Sankyo Company, Limited |
Nuevos análogos de nucleósidos y oligonucleótidos
|
|
WO2001062738A1
(en)
|
2000-02-22 |
2001-08-30 |
Banyu Pharmaceutical Co., Ltd. |
Novel imidazoline compounds
|
|
JP2002253259A
(ja)
|
2001-03-02 |
2002-09-10 |
Bio Applied Systems:Kk |
抗ビスフェノールａ抗体をコードする遺伝子、組換えタンパク質およびその製造方法
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
SI1461359T1
(sl)
|
2002-01-18 |
2007-06-30 |
Pf Medicament |
Nova anti IGF-IR protitelesa in njihova uporaba
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
EP1432724A4
(en)
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
RNA inhibition mediated inhibition of MAP KINASE GENES
|
|
JP4828795B2
(ja)
|
2002-03-11 |
2011-11-30 |
モメンタ ファーマシューティカルズ インコーポレイテッド |
硫酸化多糖類の分析
|
|
WO2004046160A2
(en)
|
2002-11-18 |
2004-06-03 |
Santaris Pharma A/S |
Amino-lna, thio-lna and alpha-l-oxy-ln
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
WO2004058717A1
(en)
|
2002-12-20 |
2004-07-15 |
X-Ceptor Therapeutics, Inc. |
Isoquinolinone derivatives and their use as therapeutic agents
|
|
DK1592793T3
(da)
|
2003-02-10 |
2009-10-26 |
Santaris Pharma As |
Oligomeriske forbindelser for modulation af Survivin ekspression
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
WO2005058244A2
(en)
|
2003-12-15 |
2005-06-30 |
Alexion Pharmaceuticals, Inc. |
Novel anti-dc-sign antibodies
|
|
WO2006022688A1
(en)
|
2004-08-06 |
2006-03-02 |
Applera Corporation |
Diagnosis of pancreatic cancer by using pancreatic targets
|
|
US8431558B2
(en)
|
2004-11-01 |
2013-04-30 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US7807619B2
(en)
|
2004-11-01 |
2010-10-05 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
WO2006091796A2
(en)
|
2005-02-22 |
2006-08-31 |
Acucela, Inc. |
Compositions and methods for diagnosing and treating retinal diseases
|
|
WO2007089612A2
(en)
|
2006-01-30 |
2007-08-09 |
President And Fellows Of Harvard College |
Methods and compositions for treating and preventing bacterial infections
|
|
DK3438131T3
(da)
|
2006-02-10 |
2022-04-11 |
Life Technologies Corp |
Oligosaccharidmodifikation og mærkning af proteiner
|
|
JP2009536222A
(ja)
|
2006-05-05 |
2009-10-08 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
Ｐｃｓｋ９の発現を調節するための化合物および方法
|
|
SI2049664T1
(sl)
|
2006-08-11 |
2012-04-30 |
Prosensa Technologies Bv |
Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev
|
|
ES2526295T5
(es)
|
2006-10-18 |
2021-05-04 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
|
EP2149605B1
(en)
|
2007-03-22 |
2013-07-03 |
Santaris Pharma A/S |
Short RNA antagonist compounds for the modulation of target mRNA
|
|
WO2009005793A2
(en)
|
2007-06-29 |
2009-01-08 |
Avi Biopharma, Inc. |
Tissue specific peptide conjugates and methods
|
|
PL2188313T3
(pl)
|
2007-08-21 |
2018-04-30 |
Amgen, Inc. |
Białka wiążące ludzki antygen c-fms
|
|
EP2274423A2
(en)
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
WO2009144481A2
(en)
|
2008-05-30 |
2009-12-03 |
Isis Innovation Limited |
Conjugates for delivery of biologically active compounds
|
|
WO2009149281A1
(en)
|
2008-06-04 |
2009-12-10 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Immunotoxins and uses thereof
|
|
BR122020021379B1
(pt)
|
2008-10-24 |
2021-05-11 |
Sarepta Therapeutics, Inc. |
oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
|
|
AU2009310557B2
(en)
|
2008-10-27 |
2014-09-11 |
Academisch Ziekenhuis Leiden |
Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA
|
|
EP2421971B1
(en)
|
2009-04-24 |
2016-07-06 |
BioMarin Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
WO2011107989A1
(en)
|
2010-03-01 |
2011-09-09 |
Lostam Biopharmaceuticals Ltd |
Improved therapeutic antibodies against flagellated pseudomonas aeruginosa
|
|
US8734799B2
(en)
|
2010-04-13 |
2014-05-27 |
The Regents Of The University Of California |
Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
|
|
SI2528625T1
(sl)
|
2010-04-15 |
2013-11-29 |
Spirogen Sarl |
Pirolobenzodiazepini in njihovi konjugati
|
|
EP2563753B9
(en)
|
2010-04-27 |
2016-07-06 |
SynAffix B.V. |
Fused cyclooctyne compounds and their use in metal-free click reactions
|
|
RU2012157167A
(ru)
|
2010-07-12 |
2014-08-20 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Полифункциональные антительные конъюгаты
|
|
EP2595663A4
(en)
|
2010-07-19 |
2014-03-05 |
Isis Pharmaceuticals Inc |
MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION
|
|
CA2818173C
(en)
|
2010-11-30 |
2022-05-03 |
Genentech, Inc. |
Low affinity blood brain barrier receptor antibodies and uses therefor
|
|
BR112013014527A2
(pt)
|
2010-12-20 |
2017-03-07 |
Genentech Inc |
anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
|
|
EP2673361B1
(en)
|
2011-02-08 |
2016-04-13 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
AU2012246822B2
(en)
|
2011-04-22 |
2017-05-25 |
Biomarin Technologies B.V. |
New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1)
|
|
CN107080847A
(zh)
|
2011-06-24 |
2017-08-22 |
森彻斯有限公司 |
细胞外靶向药物缀合物
|
|
WO2013036748A1
(en)
|
2011-09-09 |
2013-03-14 |
Berry, Lana, L. |
Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides
|
|
EP2788026A4
(en)
|
2011-12-05 |
2015-08-05 |
Univ Duke |
V1V2 IMMUNOGENIC
|
|
WO2013086207A1
(en)
|
2011-12-06 |
2013-06-13 |
The Ohio State University |
Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
|
|
AU2013203422A1
(en)
|
2012-01-06 |
2013-07-18 |
Bioalliance C.V. |
Anti-transferrin receptor antibodies and methods using same
|
|
BR112014020826A8
(pt)
|
2012-02-24 |
2017-09-19 |
Stem Centrx Inc |
Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
|
|
CA2907072A1
(en)
|
2012-03-16 |
2013-09-19 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of dmpk
|
|
LT2841578T
(lt)
|
2012-04-23 |
2017-09-25 |
Biomarin Technologies B.V. |
Rnr moduliuojantys oligonukleotidai su pagerintomis savybėmis, skirti neuromuskulinių susirgimų gydymui
|
|
EP2900821B1
(en)
|
2012-09-25 |
2020-04-01 |
Genzyme Corporation |
Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
|
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
|
CN105142672B
(zh)
|
2012-10-23 |
2019-04-05 |
西纳福克斯股份有限公司 |
经修饰的抗体、抗体-缀合物及其制备方法
|
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
ES2731681T3
(es)
|
2013-02-22 |
2019-11-18 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
|
|
EP3594240B1
(en)
|
2013-05-20 |
2023-12-06 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies and methods of use
|
|
US20160107999A1
(en)
|
2013-05-24 |
2016-04-21 |
Synaffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
CA2921457A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Heterochromatin forming non-coding rnas
|
|
KR20160047567A
(ko)
|
2013-08-28 |
2016-05-02 |
스템센트알엑스 인코포레이티드 |
조작된 항-dll3 접합체 및 사용 방법
|
|
US20160237430A1
(en)
|
2013-09-23 |
2016-08-18 |
President And Fellows Of Harvard College |
Allele-specific rna silencing for the treatment of hypertrophic cardiomyopathy
|
|
US20160235861A1
(en)
|
2013-10-14 |
2016-08-18 |
SynAffix. B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
US9987373B2
(en)
|
2013-10-14 |
2018-06-05 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
US10004814B2
(en)
|
2013-11-11 |
2018-06-26 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
|
|
US10344284B2
(en)
|
2013-11-14 |
2019-07-09 |
Lina A. Shehadeh |
Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
|
|
US10266502B2
(en)
|
2014-01-24 |
2019-04-23 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
US11168085B2
(en)
|
2014-01-24 |
2021-11-09 |
Synaffix B.V. |
Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
|
|
JP6750148B2
(ja)
|
2014-04-25 |
2020-09-02 |
公益財団法人野口研究所 |
糖鎖切断抗体の製造方法及び均一糖鎖抗体
|
|
EP3795687A1
(en)
|
2014-05-23 |
2021-03-24 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
|
EP4148138A1
(en)
|
2014-08-04 |
2023-03-15 |
SynAffix B.V. |
Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
EP3185889B1
(en)
|
2014-08-11 |
2020-07-15 |
Shire Human Genetic Therapies, Inc. |
Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
|
|
EP3197494A1
(en)
|
2014-09-25 |
2017-08-02 |
Inserm |
Immunological treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
|
|
CN107106701B
(zh)
|
2014-10-03 |
2020-11-06 |
西纳福克斯股份有限公司 |
磺酰胺接头、其缀合物及制备方法
|
|
EP3218411B1
(en)
|
2014-11-14 |
2022-01-12 |
Ossianix, Inc. |
Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
|
|
US10508151B2
(en)
|
2014-11-19 |
2019-12-17 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
TN2017000178A1
(en)
|
2014-11-21 |
2018-10-19 |
Merck Sharp & Dohme |
Insulin receptor partial agonists
|
|
EP3262056A4
(en)
|
2015-02-27 |
2018-09-19 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
WO2016170186A1
(en)
|
2015-04-23 |
2016-10-27 |
Synaffix B.V. |
PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE
|
|
BR112017023862A2
(pt)
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
AU2016264471B2
(en)
|
2015-05-19 |
2022-01-27 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
EA039366B1
(ru)
|
2015-06-24 |
2022-01-19 |
Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. |
Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
|
|
RU2737637C2
(ru)
|
2015-07-22 |
2020-12-01 |
Инатерис |
Антитела против tfr и их применение при лечении пролиферативных и воспалительных расстройств
|
|
IL295755A
(en)
|
2015-10-09 |
2022-10-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
EP3858993A1
(en)
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
DK3386534T3
(da)
|
2015-12-08 |
2020-11-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
UA124622C2
(uk)
|
2015-12-18 |
2021-10-20 |
ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. |
Кон'юговані імуноглобуліни з c-кінцевим лізином
|
|
US10874746B2
(en)
|
2016-02-08 |
2020-12-29 |
Synaffix B.V. |
Sulfamide linkers for use in bioconjugates
|
|
EP3416671A4
(en)
|
2016-02-19 |
2019-10-30 |
Genisphere, LLC |
NUCLEIC ACID CARRIER AND THERAPEUTIC METHODS OF USE
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
FR3049951A1
(fr)
|
2016-04-12 |
2017-10-13 |
Univ Rabelais Francois |
Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
|
|
CN109462995A
(zh)
|
2016-05-04 |
2019-03-12 |
波涛生命科学有限公司 |
生物活性剂的方法和组合物
|
|
EP3922260A3
(en)
|
2016-05-24 |
2022-06-15 |
Merck Sharp & Dohme Corp. |
Insulin receptor partial agonists and glp-1 analogues
|
|
BR112018074453A2
(pt)
|
2016-05-27 |
2019-03-19 |
Abbvie Biotherapeutics Inc. |
proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
|
|
DK3473270T5
(da)
|
2016-06-20 |
2024-09-09 |
Genahead Bio Inc |
Konjugat af antistof-lægemiddel
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
KR102497564B1
(ko)
|
2016-12-26 |
2023-02-07 |
제이씨알 파마 가부시키가이샤 |
혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
US20190336615A1
(en)
*
|
2017-01-27 |
2019-11-07 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
DK3635009T3
(da)
|
2017-06-07 |
2026-03-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
WO2019023257A1
(en)
|
2017-07-24 |
2019-01-31 |
Quantum-Si Incorporated |
HIGH INTENSITY MARKED REAGENT COMPOSITIONS AND SEQUENCING METHODS
|
|
MX2020003130A
(es)
|
2017-09-22 |
2020-09-25 |
Avidity Biosciences Inc |
Composiciones y metodos de induccion de salto de exon en acidos nucleicos-polipeptidos.
|
|
EP3691657A4
(en)
|
2017-10-04 |
2021-07-21 |
Avidity Biosciences, Inc. |
NUCLEIC ACID POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
|
AU2018378812B2
(en)
|
2017-12-06 |
2025-05-22 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
|
EP3735252A4
(en)
|
2018-01-04 |
2021-10-06 |
Avidity Biosciences, Inc. |
HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
|
|
IL276327B2
(en)
|
2018-02-05 |
2024-05-01 |
Japan Chem Res |
Method for delivering drug to muscle
|
|
US12258597B2
(en)
|
2018-02-07 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for therapeutic protein delivery
|
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
SG11202100928QA
(en)
|
2018-08-02 |
2021-02-25 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
IL280536B2
(en)
|
2018-08-02 |
2024-12-01 |
Dyne Therapeutics Inc |
Complexes targeting transferrin receptor and uses thereof
|
|
WO2020028842A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US20210317226A1
(en)
|
2018-08-02 |
2021-10-14 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
CA3108282A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP3829645A4
(en)
|
2018-08-02 |
2022-05-18 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF PROGRESSIVE FIBRODYSPLASIA OSSIFIANS
|
|
EP3830130A4
(en)
|
2018-08-02 |
2022-05-18 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
KR20210086601A
(ko)
|
2018-08-02 |
2021-07-08 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도
|
|
WO2020028836A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
AU2019314538B2
(en)
|
2018-08-02 |
2025-03-13 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
IT201800009682A1
(it)
|
2018-10-22 |
2020-04-22 |
Ice Spa |
Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive
|
|
CN113260384A
(zh)
|
2018-11-05 |
2021-08-13 |
西纳福克斯股份有限公司 |
用于靶向表达trop-2的肿瘤的抗体缀合物
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
WO2020163817A1
(en)
|
2019-02-08 |
2020-08-13 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
CN113677374A
(zh)
|
2019-04-08 |
2021-11-19 |
国立大学法人东京医科齿科大学 |
肌疾病治疗用药物组合物
|
|
US12006499B2
(en)
|
2019-06-06 |
2024-06-11 |
Avidity Biosciences, Inc. |
Una amidites and uses thereof
|
|
CN114375296A
(zh)
|
2019-06-06 |
2022-04-19 |
艾维迪提生物科学公司 |
核酸多肽组合物及其用途
|
|
CN119874910A
(zh)
|
2019-06-07 |
2025-04-25 |
达因疗法公司 |
制备蛋白质-寡核苷酸复合物的方法
|
|
US20240148891A1
(en)
|
2019-10-18 |
2024-05-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3166370A1
(en)
|
2019-11-27 |
2021-06-03 |
Dtx Pharma, Inc. |
Compounds and methods for the treatment of duchenne muscular dystrophy
|
|
WO2021142269A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
|
|
CA3163608A1
(en)
|
2020-01-10 |
2021-07-15 |
Romesh R. Subramanian |
Muscle-targeting complexes and uses thereof
|
|
CA3163283A1
(en)
*
|
2020-01-10 |
2021-07-15 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
KR20220125801A
(ko)
|
2020-01-10 |
2022-09-14 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
|
WO2021142217A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Thereapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of milck1
|
|
WO2021142331A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
|
|
WO2021142260A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of acvr1
|
|
US20230203180A1
(en)
|
2020-01-10 |
2023-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
AU2021206234A1
(en)
|
2020-01-10 |
2022-09-01 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
JP7780691B2
(ja)
|
2020-01-10 |
2025-12-05 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
|
|
US20230117883A1
(en)
|
2020-01-24 |
2023-04-20 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
CN115427059A
(zh)
|
2020-01-31 |
2022-12-02 |
达因疗法公司 |
抗转铁蛋白受体（tfr）抗体及其用途
|
|
US20230103793A1
(en)
|
2020-01-31 |
2023-04-06 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
SI4126066T1
(sl)
|
2020-03-27 |
2026-04-30 |
Avidity Biosciences, Inc. |
Sestavki in postopki zdravljenja mišične distrofije
|
|
WO2021226107A1
(en)
|
2020-05-05 |
2021-11-11 |
Avidity Biosciences, Inc. |
Compositions and methods of treating pompe disease
|
|
EP4185320A4
(en)
|
2020-07-23 |
2025-10-08 |
Dyne Therapeutics Inc |
MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
|
|
KR20230046297A
(ko)
|
2020-07-23 |
2023-04-05 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
|
KR20230041760A
(ko)
|
2020-07-23 |
2023-03-24 |
다인 세라퓨틱스, 인크. |
항-트랜스페린 수용체 (tfr) 항체 및 그의 용도
|
|
JP2023535078A
(ja)
|
2020-07-23 |
2023-08-15 |
ダイン セラピューティクス，インコーポレーテッド |
筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用
|
|
CN116194470B
(zh)
|
2020-07-23 |
2025-10-03 |
达因疗法公司 |
肌肉靶向复合物及其用途
|
|
MX2023000984A
(es)
|
2020-07-23 |
2023-05-03 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
|
|
EP4208173A4
(en)
|
2020-09-03 |
2025-11-26 |
Dyne Therapeutics Inc |
PROCESSES FOR PREPARING PROTEIN-OLIGONUCLEOTIC COMPLEXES
|
|
CA3189065A1
(en)
|
2020-09-11 |
2022-03-17 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
|
|
IL303332A
(en)
|
2020-12-04 |
2023-07-01 |
Dyne Therapeutics Inc |
Antibody-oligonucleotide complexes and their uses
|
|
CA3202832A1
(en)
|
2020-12-31 |
2022-07-07 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP4271478A4
(en)
|
2020-12-31 |
2025-03-26 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR TREATING FACIOSCAPULOHUMERAL MYOPATHY
|
|
EP4314016A1
(en)
|
2021-03-31 |
2024-02-07 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
|
EP4314298A1
(en)
|
2021-04-02 |
2024-02-07 |
Avidity Biosciences, Inc. |
Antibody-oligonucleotide conjugate and antibody-peptide-oligonucleotide conjugate compositions and methods of inducing exon skipping
|
|
US20240294921A1
(en)
|
2021-06-21 |
2024-09-05 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
CN118251238A
(zh)
|
2021-06-21 |
2024-06-25 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗弗里德赖希共济失调的用途
|
|
WO2022270585A1
(ja)
|
2021-06-23 |
2022-12-29 |
日本新薬株式会社 |
アンチセンスオリゴマーの組み合わせ
|
|
JP2024525612A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
AU2022309238A1
(en)
|
2021-07-09 |
2024-01-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
JP2024525611A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
WO2023283629A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
CA3226301A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
KR20240035823A
(ko)
|
2021-07-09 |
2024-03-18 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
|
|
JP2024525608A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体および製剤
|
|
US20240382513A1
(en)
|
2021-07-09 |
2024-11-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
JP2024527362A
(ja)
|
2021-07-09 |
2024-07-24 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
JPWO2023022229A1
(enExample)
|
2021-08-19 |
2023-02-23 |
|
|
|
US20240390508A1
(en)
|
2021-08-21 |
2024-11-28 |
Takeda Pharmaceutical Company Limited |
Human transferrin receptor binding peptide-drug conjugate
|
|
EP4401777A4
(en)
|
2021-09-16 |
2025-08-13 |
Dyne Therapeutics Inc |
DOSAGE OF MUSCLE-TARGETING COMPLEXES TO TREAT DYSTROPHINOPATHIES
|
|
AU2022377070A1
(en)
|
2021-11-01 |
2024-04-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating dystrophinopathies
|
|
WO2023086864A1
(en)
|
2021-11-12 |
2023-05-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy
|
|
WO2023121444A1
(en)
|
2021-12-22 |
2023-06-29 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders
|
|
US20250057971A1
(en)
|
2021-12-22 |
2025-02-20 |
Sapreme Technologies B.V. |
Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
|
|
JP2025500481A
(ja)
|
2021-12-22 |
2025-01-09 |
サプリーム テクノロジーズ，ベー．フェー． |
筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物
|
|
WO2023168427A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
|
JP2025079347A
(ja)
|
2022-03-11 |
2025-05-22 |
日本新薬株式会社 |
キャリアペプチドが連結された核酸
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
CN119256008A
(zh)
|
2022-04-15 |
2025-01-03 |
达因疗法公司 |
用于治疗强直性肌营养不良的肌肉靶向复合物及其用途
|
|
WO2023201318A1
(en)
|
2022-04-15 |
2023-10-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
KR20250004771A
(ko)
|
2022-04-15 |
2025-01-08 |
다인 세라퓨틱스, 인크. |
근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체의 투여
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
EP4551230A2
(en)
|
2022-07-06 |
2025-05-14 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
JP2025522877A
(ja)
|
2022-07-06 |
2025-07-17 |
ダイン セラピューティクス，インコーポレーテッド |
Ｃｎｓ標的化複合体およびその使用
|
|
EP4612185A1
(en)
|
2022-10-31 |
2025-09-10 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for skipping exon 45 of a dmd gene
|
|
KR20250116673A
(ko)
|
2022-11-21 |
2025-08-01 |
펩젠 인크. |
세포-침투 펩티드, 그의 접합체 및 그의 사용 방법
|
|
IL321969A
(en)
|
2023-01-10 |
2025-09-01 |
Ausperbio Therapeutics Inc |
Multi-stranded antisense oligonucleotides modified for use
|
|
WO2024182358A1
(en)
|
2023-02-27 |
2024-09-06 |
Dyne Therapeutics, Inc. |
Methods and compositions for inhibiting progression of intramuscular fibrosis
|
|
WO2025076486A1
(en)
|
2023-10-06 |
2025-04-10 |
Dyne Therapeutics, Inc. |
Biomarkers for repeat expansion diseases
|